A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas

BACKGROUND: This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy. METHODS: Patients with advanced biliary adenocarcinomas received gemcitabine 1000 mg m(−2) and cisplatin 25 mg m(−2) on a 2 weeks on/1 week off cycle and sorafenib 40...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Lee, J K, Capanu, M, O'Reilly, E M, Ma, J, Chou, J F, Shia, J, Katz, S S, Gansukh, B, Reidy-Lagunes, D, Segal, N H, Yu, K H, Chung, K-Y, Saltz, L B, Abou-Alfa, G K
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2013
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3749586/
https://ncbi.nlm.nih.gov/pubmed/23900219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.432
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items